medigraphic.com
ISSN 2007-8560 (Print)
Órgano Oficial de Difusión Científica de la Federación Mexicana de Colegios de Ortopedia y Traumatología, A.C. (FEMECOT)

2010, Number 1

<< Back Next >>

Ortho-tips 2010; 6 (1)

Estructura y metabolismo del tejido óseo

Alcantar LE

Language: Spanish
References: 15
Page: 7-13
PDF size: 77.64 Kb.


ABSTRACT

Bone tissue is in constant formation and reabsorption to maintain its volume, process known as bone remodeling or turnover. Through this process, the bones renew 5 to 10% of its total volume per year. This process involves basically three types of cells: the osteoblasts, bone forming cells, osteocytes which form lagoons where the inorganic materials are deposited to give strength to the bone, and the osteoclasts responsible of reabsorption. In order this process carry out in a balanced way, requires the participation of important chemical mediators like hormones and other local sustains, as well as environmental and nutritional factors.


REFERENCES

  1. Seeman E, Delmas PD. Mechanisms of disease: Bone quality-The material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250.

  2. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423(6937): 332-336.

  3. Robey PG. Vertebrate mineralized matrix proteins: structure and function. Connect Tissue Res 1996; 34(1-4): 131-136.

  4. Ott SM. Sclerostin and WNT signaling the pathway to bone strength. J Clin Endocrinol Metab 2005; 90(12): 6741-6743.

  5. Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005; 280(39): 33132-33140.

  6. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008; 75(10): 739-750.

  7. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005; 26(4): 97-122.

  8. Seibel MJ. Biochemical markers of bone turnover: part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006; 27: 123-138.

  9. Coleman RE, Major P, Lipton A, et al. Predictive value of bone reabsorption and formation markers in cancer patients with bone metastases receiving the biphosphonate zoledronic acid. J Clin Oncol 2005; 23(22): 4925.

  10. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90(5): 2762-2767.

  11. Vega D, Maalouf NM, Sakhaee K. CLINICAL: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92(12): 4514-4521.

  12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22(4): 549-553.

  13. Papadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol 2008; 23(4): 497-506.

  14. Datta HK, Ng WF, Walker JA, et al. The cell biology of bone metabolism. J Clin Pathol 2008; 61(5): 577-587.

  15. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130(3): 456-469.




2020     |     www.medigraphic.com